Catalyst Wire Dossier Catalyst Wire Dossier

Ribociclib (LEE011)

ribociclib · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Ribociclib (LEE011), covering 2019-06-03 to 2025-10-10. Get the full timeline:

Most recent: Clinical Trial Update: Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors [Phase 1]

See pricing